Page 71 - 2018_09-Mondo

TGFβ1-mediated inhibition of MDS- and AML-derived MSC
Biotechnol. 2013;31(1):46-53.
20. Subramanian A, Tamayo P, Mootha VK, et
al. Gene set enrichment analysis: a knowl- edge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
21. Bruns I, Cadeddu RP, Brueckmann I, et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoi- etic stem and progenitor cells. Blood. 2012;120(13):2620-2630.
22. Hayashi T, Hideshima T, Nguyen AN, et al. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004;10(22):7540-7546.
23. Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008;112(8):3434-3443.
24. Akiyama T, Matsunaga T, Terui T, et al. Involvement of transforming growth factor- beta and thrombopoietin in the pathogene- sis of myelodysplastic syndrome with myelofibrosis. Leukemia. 2005;19(9):1558- 1566.
25. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115(4):881-894.
26. Blank U, Karlsson S. TGF-beta signaling in the control of hematopoietic stem cells. Blood. 2015;125(23):3542-3550.
27. Garbe A, Spyridonidis A, Mobest D, et al. Transforming growth factor-beta 1 delays formation of granulocyte-macrophage colony-forming cells, but spares more prim- itive progenitors during ex vivo expansion of CD34+ haemopoietic progenitor cells. Br J
Haematol. 1997;99(4):951-958.
28. Sitnicka E, Ruscetti FW, Priestley GV, Wolf
NS, Bartelmez SH. Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopu- lating hematopoietic stem cells. Blood. 1996;88(1):82-88.
29. Krause DS, Fulzele K, Catic A, et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med. 2013;19(11):1513-1517.
results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica. 2012;97 (4):529-533.
36. Deeg HJ, Gotlib J, Beckham C, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia. 2002;16(2):162-164.
37. Isufi I, Seetharam M, Zhou L, et al. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007;27(7):543-
30. Dominici M, Le Blanc K, Mueller I, et al.
Minimal criteria for defining multipotent 552.
mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8 (4):315-317.
31. Bhagat TD, Chen S, Bartenstein M, et al. Epigenetically aberrant stroma in MDS propagates disease via Wnt/beta-catenin activation. Cancer Res. 2017;77(18):4846- 4857.
32. Chandran P, Le Y, Li Y, et al. Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic pro- genitors. Leuk Res. 2015;39(4):486-493.
33. Kim JA, Shim JS, Lee GY, et al. Microenvironmental remodeling as a parameter and prognostic factor of heteroge- neous leukemogenesis in acute myeloge- nous leukemia. Cancer Res. 2015;75(11): 2222-2231.
34. Bachegowda L, Gligich O, Mantzaris I, et al. Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol. 2013;6:50.
35. Baron F, Suciu S, Amadori S, et al. Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final
38. Bhagat TD, Zhou L, Sokol L, et al. miR-21 mediates hematopoietic suppression in MDS by activating TGF-beta signaling. Blood. 2013;121(15):2875-2881.
39. Zhou L, McMahon C, Bhagat T, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011;71(3): 955-963.
40. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-beta superfami- ly ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414.
41. Iancu-Rubin C, Mosoyan G, Wang J, et al. Stromal cell-mediated inhibition of erythro- poiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013;41(2):155-166.e17.
42. Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid- derived suppressor cells. J Clin Invest. 2013;123(11):4595-4611.
43. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152.
haematologica | 2018; 103(9)
1471